- KR₩367bn
- KR₩322bn
- KR₩65bn
- 75
- 35
- 57
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.39 | ||
| PEG Ratio (f) | 0.43 | ||
| EPS Growth (f) | 32.18% | ||
| Dividend Yield (f) | 1.09% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.87 | ||
| Price to Tang. Book | 3.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.64 | ||
| EV to EBITDA | 10.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.32% | ||
| Return on Equity | 21.22% | ||
| Operating Margin | 43.1% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 17,020.66 | 24,366.6 | 37,418.2 | 56,718.82 | 65,042.9 | 84,500 | 132,000 | 42.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +145.28 | +70.04 | +31.15 | +61.71 | +17.14 | +25.99 | +43.41 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioPlus Co Ltd is a Korea-based company principally engaged in the medical device business. The Company is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 23rd, 2003
- Public Since
- September 27th, 2021
- No. of Shareholders
- 37,826
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 57,187,428
- Address
- 227, Dogok-ro, Gangnam-gu, SEONGNAM, 13209
- Web
- https://bioplus.co.kr/
- Phone
- +82 25211898
- Auditors
- Woori Accountants
Upcoming Events for 099430
Similar to 099430
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
Ahn-Gook Pharmaceutical Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:04 UTC, shares in BioPlus Co are trading at KR₩6,420. This share price information is delayed by 15 minutes.
Shares in BioPlus Co last closed at KR₩6,420 and the price had moved by -4.76% over the past 365 days. In terms of relative price strength the BioPlus Co share price has underperformed the FTSE Developed Asia Pacific Index by -0.59% over the past year.
The overall consensus recommendation for BioPlus Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
The BioPlus Co dividend yield is 1.09% based on the trailing twelve month period.
Last year, BioPlus Co paid a total dividend of KR₩70, and it currently has a trailing dividend yield of 1.09%. We do not have any data on when BioPlus Co is to next pay dividends.
We do not have data on when BioPlus Co is to next pay dividends. The historic dividend yield on BioPlus Co shares is currently 1.09%.
To buy shares in BioPlus Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩6,420, shares in BioPlus Co had a market capitalisation of KR₩367bn.
Here are the trading details for BioPlus Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 099430
Based on an overall assessment of its quality, value and momentum BioPlus Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BioPlus Co is KR₩9,500. That is 47.98% above the last closing price of KR₩6,420.
Analysts covering BioPlus Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩546 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioPlus Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -7.45%.
As of the last closing price of KR₩6,420, shares in BioPlus Co were trading -8.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioPlus Co PE ratio based on its reported earnings over the past 12 months is 10.39. The shares last closed at KR₩6,420.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BioPlus Co's management team is headed by:
- Hyun Kyu Jung - CHM